5. References

  1. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www-micromedexsolutions-com.libproxy.uthscsa.edu/ (cited: February 18, 2021).
  2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2021. Available at: http://clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed February 18, 2021.
  3. Facts and Comparisons eAnswers [database online]. Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2021; February 18, 2021.
  4. American Society of Health-System Pharmacists. 2021. AHFS Drug Information® - 2021st Ed. Bethesda, MD. American Society of Health-System Pharmacists®. ISBN-10: 1-58528-654-0, ISBN-13: 978-1-58528-654-6. ISSN: 8756-6028. STAT!Ref Online Electronic Medical Library.  https://online.statref.com/document/cQfe8yqMRNqgSGqm4Qo8Qj. Accessed February 18, 2021.
  5. Fluoxetine capsules, delayed-release capsules (Prozac®, Prozac® Weekly™) package insert. Eli Lilly and Company, April 2020.
  6. Fluoxetine pulvules package insert. Dista Products Company, April 2020.
  7. Paroxetine tablets (Pexeva®) package insert. Apotex Corp., June 2020.
  8. Paroxetine capsules (Brisdelle®) package insert. Sebela Pharmaceuticals Inc., October 2017.
  9. Olanzapine and fluoxetine (Symbyax®) package insert. Eli Lilly and Company, October 2020.
  10. U.S. Food and Drug Administration. FDA drug safety communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available at:  http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm. Accessed February 18, 2021.
  11. American Psychiatric Association. Work Group on Major Depressive Disorder.  Practice guideline for the treatment of patients with major depressive disorder Practice guideline for the treatment of patients with major depressive disorder, 3rd edition; 2010. Available at:  http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed February 18, 2021.
  12. Zuckerbrot RA, Cheung A, Jensen PS, et al. Guidelines for adolescent depression in primary care (GLAD-PC): Part I. Practice preparation, identification, assessment, and initial management. Pediatrics. 2018;141(3):e20174081. 
  13. Cheung AH, Zuckerbrot RA, Jensen PS, et al. Guidelines for adolescent depression in primary care (GLAD- PC): Part II. Treatment and ongoing management. Pediatrics. 2018;141(3):e20174082. 
  14. Freeman EW, Rickels K, Sammel MD, et al. Time to relapse after short- or long-term treatment of severe premenstrual syndrome with sertraline. Arch Gen Psychiatry. 2009; 66(5):537-44.
  15. Steiner M, Ravindran AV, LeMelledo JM, et al. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. J Clin Psychiatry. 2008;69(6):991-8.
  16. Busti AJ, Lehew DS, Nuzum DS, Daves BJ. Part 1: How does the opioid analgesic tramadol (Ultram®; Ultram ER®, Ultracet®) increase the risk for developing serotonin syndrome in patients taking SSRI antidepressant medications? Pharmacol Wkly. 2009;1(9):1-4.
  17. Taylor WD. Depression in the elderly. N Engl J Med. 2014;371:1228-36.
  18. Clark MS, Jansen KL, Cloy JA. Treatment of childhood and adolescent depression. Am Fam Physician. 2012;86(5):442-8.
  19. Bentley SM, Pagalilauan GL, Simpson SA. Major depression. Med Clin N Am. 2014;98:981-1005.
  20. Kovich H, DeJong A. Common questions about the pharmacologic management of depression in adults. Am Fam Physician. 2015;92(2):94-100.
  21. Texas Health and Human Services. Psychotropic medication utilization parameters for children and youth in Texas public behavioral health (6th version), June 2019. Available at: https://hhs.texas.gov/sites/default/files/documents/doing-business-with-hhs/provider-portal/facilities-regulation/psychiatric/psychotropic-medication-utilization-parameters.pdf. Accessed February 18, 2021.